Sangamo BioSciences Inc. (SGMO) Company Profile
Sangamo Biosciences, Inc. engages in the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP transcription factors (ZFP TFs), proteins that could be used to turn genes on or off; and ZFP nucleases (ZFNs), proteins that enable to modify DNA sequences in various ways. The company?s principal ZFP therapeutic include SB-509, a plasmid formulation of a ZFP TF activator of the vascular endothelial growth factor-A (VEGF-A) gene that is in a Phase 2b clinical trial for the treatment of severe diabetic neuropathy; and in a Phase 2 clinical trial in for the treatment of amyotrophic lateral sclerosis, as well as in preclinical animal studies for spinal cord injury, traumatic brain injury, and stroke. It is also developing SB-728-T, a ZFN-modified T-cell product, which is in Phase 1/2 clinical trial and two Phase 1 trials for the treatment of HI V/AIDS. In addition, the company develops SB-313xTZ, a ZFN-based therapeutic that is in Phase 1 clinical trial for the treatment of glioblastoma multiforme, a type of brain cancer. Further, it has preclinical development programs of ZFP therapeutics in the areas of Parkinson?s disease, hemophilia B, and neuropathic pain; and neuroregenerative programs in spinal cord injury, traumatic brain injury, and stroke. Additionally, the company has research stage programs in the areas of monogenic diseases and genetic conditions that result from a defect in a single gene, including hemophilia and other hemoglobinopathies, and immunodeficiencies. It has collaboration agreements with Sigma-Aldrich Corporation; Dow AgroSciences LLC; Pfizer Inc.; Genentech, Inc.; Open Monoclonal Technology, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was founded in 1995 and is headquartered in Richmond, California.
News about SGMO
Insider Selling: Sangamo Therapeutics Inc (SGMO) CFO Sells 5,000 Shares of Stock
Sangamo Therapeutics Inc (NASDAQ:SGMO) CFO Kathy Yi sold 5,000 shares of the company’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $14.66, for a total value of $73,300.00. Following the transact...Read More>>>
Sangamo Therapeutics Inc (SGMO) Position Boosted by Swiss National Bank
Swiss National Bank increased its holdings in shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) by 19.1% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 173,160 shares of the biopharmaceutical company’s st...Read More>>>
Here’s What Was Behind Sangamo’s Horrendous Week
After reporting disappointing results from an early-stage study of its promising gene-editing therapy for mucopolysaccharidosis type II (MPS II) on Sept. 5, Sangamo Therapeutics (NASDAQ:SGMO) saw its shares tumble 29%. Does the data dash hope for th...Read More>>>
Why Sangamo Therapeutics, Inc. Sank Again Today
What happened Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) were down 10.5% as of 3:34 p.m. EDT on Thursday. This marked the second consecutive day of double-digit percentage declines following the biotech's interim update from a phase 1/2 clini...Read More>>>
Is This Gene-Editing Stock Doomed?
Sangamo Therapeutics (NASDAQ:SGMO) made history on September 5 when it announced preliminary results from the first-ever clinical trial evaluating in vivo gene editing in humans, but the stock crashed, losing almost a quarter of its value that day. ...Read More>>>